LOTTE BIOLOGICS’ Post

Hey scientist, do you like #antibodies? 👨⚕️ Wanna learn how to make some against cancer targets like CXCR4? Come to my presentation at #Festivalofbiologics2024 to learn how Salipro together with Bio-Rad Laboratories made novel antibodies against CXCR4. It will be a blast!

Come see us at Festival of Biologics in the start-up zone, booth S6! We are ready to talk about how SPOC can assist your antibody and biologics drug discovery pipelines with high-throughput kinetic affinity screening! #SPOCProteomics #ProteinKineticsAtScale #kineticproteomics #drugdiscovery #aidrugdiscovery #antibodytherapeutics #FestivalofBiologicsUSA

Conference season is on! ✈️🌍✈️🌍 I look forward to presenting the PipeBio platform next week at one of the best (if not the best) antibody conferences organized by FairJourney Biologics. And for once, we will actually bring a new slide deck with some pretty exciting results from a customer collaboration. More next week. 🤓 I hardly need to mention that we will do a run or two 😀🏃♂️🏃♀️ #antibody #bioinformatics #machinelearning

D is the first letter in DCAT. It is the second letter in CDMO and Advisor. It is also the antepenultimate letter in Monday, Tuesday, Wednesday, and Thursday. These are the four days I ‘ll be in NYC for DCAT pitching various active and ongoing projects, from promoting the launch of the CDMO Advisor beta webpage, to pitching Vectron Biosolutions AS, Project Insulin, Drug Biologics Consulting, CellViva, and more! I am eager to talk to y’all. There are many ways to reach out to us. The easiest is: messaging @ 908-666-7664; or email @ bestupinan@drugbiologics.com; or DM @ LinkedIn Messaging. #dcatweek #cdmo #NYC #biotechnology

The ‘one-stop-shop’ Introduction to Drug Discovery: From Idea to Clinical Candidate course from One Nucleus will take place at the Park on 30 April. The focus is on small molecule drugs with comparisons made with biologics. Delegates will travel step-by-step along a typical drug discovery path, namely: Initiating Idea > Drug Target Protein Selection > Lead Identification > Clinical Candidate Nomination for transfer to Development. If this sounds like something you'd benefit from, find all the details here - https://ow.ly/FvZ650QXvqo

Wondering what makes KBI Biopharma different from other CDMOs? Hear it from Séverine Fagète. It's still time to engage in a conversation with her at booth 710 about your needs and find out the best custom-made solution for you. #FestivalofBiologics

What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies? Rajiv Nayar, President at HTD Biosystems and Chuck Sholtz, Vice President, Intellectual Property at Nutcracker Therapeutics explored current issues and strategies in this dynamic field from patent eligibility considerations for biologics and antibodies, strategies for prosecuting bispecific antibody patent applications around the world, and emerging trends in biologic and antibody patenting. Benjamin Pelletier, Partner at Haynes and Boone, LLP moderated the session. #LSPNFall #Patents #IntellectualProperty

For Hifas Biologics, the fungal world represents a valuable source of innovation for early drug discovery targeting multi-resistant bacterial strains. Our commitment to this goal is strong and clear. We have outlined a strategy that focuses on three fundamental pillars: ▪ Design and optimization of the mycotheca ▪ Creation of a network of strategic partners for Open Innovation Drug Discovery processes. ▪ Generation of intellectual property (IP) If you would like to learn more about our strategy and how we are approaching this important mission, we invite you to visit our website. https://lnkd.in/dQdXszeq You will find detailed information on our approach and our ongoing efforts to combat multidrug-resistant bacteria. Together, we are driving innovation in medicine and contributing to a healthier world!

🔍 Join Abzena to explore how key technologies and processes can expedite early-phase #biologics to the clinic and beyond. Learn about the latest in mammalian cell-based biologics for #MonoclonalAntibodies, fusion proteins, antibody fragments, bispecifics, and ADCs. 🔬 Discover strategies for creating robust, flexible, and cost-effective production processes to meet the rising demand for these efficacious drugs. The expert speakers will cover the impact of fully integrated end-to-end single-use technologies, advances in cell line development, and new purification platforms. Through case studies, see how Abzena uses Sartorius’ technologies and a quality by-design approach to rapidly develop and implement processes in a CDMO setting. ➡️ REGISTER HERE: https://buff.ly/3ywKyoS 🌟 Expert speakers: Dennis Yoon Priyanka Gupta #DrugDevelopment #CommercialManufacturing #CDMO #BiologicsManufacturing